BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28796362)

  • 21. Rapid progression of primary cutaneous gamma-delta T-cell lymphoma with an initial indolent clinical presentation.
    Alexander RE; Webb AR; Abuel-Haija M; Czader M
    Am J Dermatopathol; 2014 Oct; 36(10):839-42. PubMed ID: 25247673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary cutaneous CD8+ T-cell lymphoma masquerading as acral vascular syndrome.
    Le Loarer F; Barete S; Vallat L; Carre D; El Amarti R; Torres-Cabala C; Cacoub P; Sene D; Courville P; Bravard P
    Acta Derm Venereol; 2014 May; 94(3):317-9. PubMed ID: 23995595
    [No Abstract]   [Full Text] [Related]  

  • 23. CD68 expression is a discriminative feature of indolent cutaneous CD8-positive lymphoid proliferation and distinguishes this lymphoma subtype from other CD8-positive cutaneous lymphomas.
    Wobser M; Roth S; Reinartz T; Rosenwald A; Goebeler M; Geissinger E
    Br J Dermatol; 2015 Jun; 172(6):1573-1580. PubMed ID: 25524664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Indolent lymphoma of the ear].
    Valois A; Bastien C; Granel-Broca F; Cuny JF; Barbaud A; Schmutz JL
    Ann Dermatol Venereol; 2012 Dec; 139(12):818-23. PubMed ID: 23237280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD8(+) granulomatous cutaneous T-cell lymphoma: a potential association with immunodeficiency.
    Gammon B; Robson A; Deonizio J; Arkin L; Guitart J
    J Am Acad Dermatol; 2014 Sep; 71(3):555-60. PubMed ID: 24813299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pagetoid reticulosis with CD30 positivity and cytotoxic/suppressor cells.
    Jacyk WK; Grayson W; Dinkel JE; Requena L
    J Cutan Pathol; 2007 Aug; 34(8):644-7. PubMed ID: 17640236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Facial ulcerated nodules revealing primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma].
    Rolland M; Dinulescu M; Saillard C; Battistella M; Le Gall F; Lhomme F; Gangneux JP; Dupuy A; Adamski H
    Ann Dermatol Venereol; 2020 Nov; 147(11):764-768. PubMed ID: 32527516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary cutaneous small- to medium-sized CD4+ pleomorphic T-cell lymphoma: a retrospective case series and review of the provisional cutaneous lymphoma category.
    Williams VL; Torres-Cabala CA; Duvic M
    Am J Clin Dermatol; 2011 Dec; 12(6):389-401. PubMed ID: 21863906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fatal CD8+ epidermotropic cytotoxic primary cutaneous T-cell lymphoma with multiorgan involvement.
    Marzano AV; Ghislanzoni M; Gianelli U; Caputo R; Alessi E; Berti E
    Dermatology; 2005; 211(3):281-5. PubMed ID: 16205076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary cutaneous CD8+ cytotoxic T-cell lymphoma of the face with intraoral involvement, resulting in facial nerve palsy after chemotherapy.
    Travassos DC; Silveira HA; Silva EV; Panucci BZM; da Silva Filho NC; Silva PVR; Bufalino A; León JE
    J Cutan Pathol; 2022 Jun; 49(6):560-564. PubMed ID: 35001425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Indolent CD8+ lymphoid proliferation of the ear: report of two cases and review of the literature.
    Swick BL; Baum CL; Venkat AP; Liu V
    J Cutan Pathol; 2011 Feb; 38(2):209-15. PubMed ID: 21083681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary cutaneous CD8+ cytotoxic T-cell lymphoma involving the epidermis and subcutis in a young child.
    Wang L; Gao T; Wang G
    J Cutan Pathol; 2015 Apr; 42(4):271-5. PubMed ID: 25458991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary cutaneous aggressive epidermotropic CD8(+) cytotoxic T-cell lymphoma with atypical presentation.
    Kim SK; Kim YC; Kang HY
    J Dermatol; 2006 Sep; 33(9):632-4. PubMed ID: 16958809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cutaneous CD8+ squamous T-cell bullous lymphoma].
    Héliot-Hosten I; Versapuech J; Vergier B; Taieb A; Delaunay M
    Ann Dermatol Venereol; 2005 Apr; 132(4):359-61. PubMed ID: 15886565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary cutaneous aggressive epidermotropic CD8+ T cell lymphoma with a chronic and indolent course. Is this different from peripheral T cell lymphoma?
    Gomez Vazquez M; Navarra Amayuelas R
    Dermatol Online J; 2012 Mar; 18(3):11. PubMed ID: 22483522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cutaneous CD8+ Cytotoxic T-Cell Lymphoma Infiltrates: Clinicopathological Correlation and Outcome of 35 Cases.
    Wobser M; Reinartz T; Roth S; Goebeler M; Rosenwald A; Geissinger E
    Oncol Ther; 2016; 4(2):199-210. PubMed ID: 28261650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Indolent CD8(+) lymphoid proliferation of acral sites: a clinicopathologic study of six patients with some atypical features.
    Greenblatt D; Ally M; Child F; Scarisbrick J; Whittaker S; Morris S; Calonje E; Petrella T; Robson A
    J Cutan Pathol; 2013 Feb; 40(2):248-58. PubMed ID: 23189944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma: transformation from indolent to aggressive phase in association with CCR7-positive conversion.
    Kasuya A; Hirakawa S; Tokura Y
    Dermatol Online J; 2012 Oct; 18(10):5. PubMed ID: 23122012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Indolent CD8-positive lymphoid proliferation of the ear: a distinct primary cutaneous T-cell lymphoma?
    Petrella T; Maubec E; Cornillet-Lefebvre P; Willemze R; Pluot M; Durlach A; Marinho E; Benhamou JL; Jansen P; Robson A; Grange F
    Am J Surg Pathol; 2007 Dec; 31(12):1887-92. PubMed ID: 18043044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Aggressive T cytotoxic CD8+ epidermotropic cutaneous lymphoma: a case in a patient with Steinert's myotonic dystrophy].
    Du-Thanh A; Durand L; Costes V; Guillot B; Dereure O
    Ann Dermatol Venereol; 2006 Dec; 133(12):991-4. PubMed ID: 17185931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.